• Contact Us

  • Pipeline
    Lynovex (NM001) Nylexa (NM002) Novexatin (NP213) NP339 NP432

  • Technology

  • Therapeutic Focus

  • About Us
    Board and Management Investors Corporate Social Responsibility

  • News and Events
  • Follow
  • Follow
  • Follow
  • News and Events
  • About Us
    • Board and Management
    • Investors
    • Corporate Social Responsibility
  • Therapeutic Focus
  • Technology
  • Pipeline
    • NM001 (Lynovex®)
    • NM002 (Nylexa®)
    • NP213 (Novexatin®)
    • NP339
    • NP432
  • Contact Us

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Recent Posts

  • Just when we thought things were getting better…..
  • CARE CF 1 oral Lynovex clinical trial data published
  • NovaBiotics in the press
  • As world antimicrobial awareness week gets underway, our CEO shares her thoughts on the near-term outlook for antimicrobials: the economic case aligning with innovation
  • Why, in the current crisis we still need more effective, proven treatments for COVID-19

Recent Comments

  • bahis on NovaBiotics secures £1m funding for COVID 19 project
  • NovaBiotics secures £1m COVID-19 Innovate funding for Nylexa clinical development - Tricapital on NovaBiotics secures £1m funding for COVID 19 project
  • NovaBiotics secures £1m COVID-19 Innovate funding for Nylexa clinical development - Tricapital on OBE for NovaBiotics’ CEO in the Queen’s Birthday Honours List

NovaBiotics Ltd
Silverburn Crescent
Bridge of Don
Aberdeen
AB23 8EW, UK

Tel:+44 (0)1224 711377

Registered Company
No. SC272344

NovaBiotics Inc
One Boston Place,
Suite 2600,
Boston
MA, 02108

Tel:+1 866 259 4527

NovaBiotics
90 Upper George's Street,
Dun Laoghaire,
Co. Dublin,
A96 R8R9

Tel:+353 1 2712605

Registered Company
No. 642058

News and Events

About Us

Therapeutic Focus

Technology

Pipeline

Contact Us